# BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer

> **NCT02125175** · NA · COMPLETED · sponsor: **The Clatterbridge Cancer Centre NHS Foundation Trust** · enrollment: 55 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Hypofractionated IMRT boost Radiotherapy

## Key facts

- **NCT ID:** NCT02125175
- **Lead sponsor:** The Clatterbridge Cancer Centre NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-09
- **Final completion:** 2019-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125175, "BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02125175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*